Related Experiment Video

Updated: Apr 30, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.8K

Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer

Bertrand Allard1, Martin Turcotte, John Stagg

  • 1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Faculté de Pharmacie et Institut du Cancer de Montréal , 900 Rue Saint Denis, 10ième étage, Montréal H2X0X9, QC , Canada +514 890 8000 ext: 25170 ; +514 412 7661 ; john.stagg@umontreal.ca.

Expert Opinion on Therapeutic Targets
|May 7, 2014
PubMed
Abstract

Insights

Targeting CD73, an enzyme linked to poor outcomes in triple-negative breast cancer (TNBC), shows promise. Blocking CD73 and related signaling pathways may offer new therapeutic strategies for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Breast cancer remains a global health challenge, with triple-negative breast cancer (TNBC) presenting aggressive characteristics and limited treatment options.
  • The ectonucleotidase CD73 is emerging as a significant target in TNBC, showing potential for novel therapeutic interventions.
  • Research into pharmacological targeting of CD73 and adenosine receptor signaling is advancing cancer treatment development.

Purpose of the Study:

  • To review the structural and molecular characteristics of CD73.
  • To elucidate the role of CD73 in cancer development.
  • To specifically focus on the involvement of CD73 in the biology of TNBC.

Main Methods:

  • Literature review of CD73 structure and function.
  • Analysis of CD73's role in cancer biology, particularly TNBC.
  • Examination of preclinical data on CD73 targeting and its synergistic effects.

Main Results:

  • CD73 expression in TNBC correlates with adverse clinical outcomes and resistance to anthracycline chemotherapy.
  • Targeted inhibition of the CD73/A2A pathway effectively hinders tumorigenesis in preclinical models.
  • Combined blockade of CD73/A2A demonstrates synergistic effects with other anti-cancer therapies.

Conclusions:

  • CD73 is a validated therapeutic target in TNBC.
  • Development of CD73 inhibitors is strongly recommended for TNBC treatment.
  • Repositioning of A2A antagonists should be considered for cancer therapy.
Keywords:
CD73adenosine receptorsimmunosuppressiontriple negative breast cancer

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

13.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K